AbCellera Biologics (ABCL) Common Equity (2020 - 2026)

AbCellera Biologics has reported Common Equity for 7 years, with the latest figure at $938.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 8.3% year-over-year to $938.1 million; the trailing twelve-month figure through Mar 2026 stood at $938.1 million (down 8.3% YoY), and the FY2025 full-year result was $966.9 million, down 8.44% from the prior year.
• Common Equity for Q1 2026 stood at $938.1 million, down from $966.9 million in the prior quarter.
• The five-year high for Common Equity was $1.3 billion in Q3 2022, with the low at $938.1 million in Q1 2026.
• Historically, Common Equity has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• Annual changes were most pronounced in 2022 — Common Equity surged 31.13% — and 2025, when it declined 10.58%.
• AbCellera Biologics' Common Equity stood at $1.2 billion in 2022, then retreated by 6.56% to $1.2 billion in 2023, then slipped by 8.35% to $1.1 billion in 2024, then declined by 8.44% to $966.9 million in 2025, then declined by 2.98% to $938.1 million in 2026.
• The last three Common Equity figures came in at $938.1 million (Q1 2026), $966.9 million (Q4 2025), and $964.0 million (Q3 2025), per Business Quant data.